EP3184523A1 — N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[l,1'-biphenyl]-3-carboxamide hydrobromide for use in the treatment of a cell proliferative disorder of the hematologic system
Assigned to Eisai R&D Management Co Ltd · Expires 2017-06-28 · 9y expired
What this patent protects
Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide hydrobromide for use in the treatment of a cell proliferative disorder of the hematologic system.…
USPTO Abstract
Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide hydrobromide for use in the treatment of a cell proliferative disorder of the hematologic system. Also provided herein is a particular polymorph form of this compound and its use.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.